JP2012517428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517428A5 JP2012517428A5 JP2011549168A JP2011549168A JP2012517428A5 JP 2012517428 A5 JP2012517428 A5 JP 2012517428A5 JP 2011549168 A JP2011549168 A JP 2011549168A JP 2011549168 A JP2011549168 A JP 2011549168A JP 2012517428 A5 JP2012517428 A5 JP 2012517428A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- acid
- compound
- substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 78
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- -1 Substituted Chemical class 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 claims description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 125000003435 aroyl group Chemical group 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 229940045996 isethionic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229950000244 sulfanilic acid Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 10
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15173709P | 2009-02-11 | 2009-02-11 | |
| US61/151,737 | 2009-02-11 | ||
| PCT/US2010/000369 WO2010093436A2 (en) | 2009-02-11 | 2010-02-11 | Toll-like receptor modulators and treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517428A JP2012517428A (ja) | 2012-08-02 |
| JP2012517428A5 true JP2012517428A5 (cg-RX-API-DMAC7.html) | 2013-02-21 |
Family
ID=42173783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549168A Pending JP2012517428A (ja) | 2009-02-11 | 2010-02-11 | Ｔｏｌｌ様レセプター調節因子および疾患の処置 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8729088B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2396328A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012517428A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110117705A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102439011B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010214112B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1008383A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2752074A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA019768B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL214572A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011008500A (cg-RX-API-DMAC7.html) |
| SG (1) | SG173617A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010093436A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201106268B (cg-RX-API-DMAC7.html) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| CA2653941C (en) | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Substituted amino purine derivatives and uses thereof |
| US8338593B2 (en) * | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| EA019151B1 (ru) | 2007-02-07 | 2014-01-30 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Конъюгаты синтетических агонистов tlr и их применение |
| JP2011511073A (ja) * | 2008-02-07 | 2011-04-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｌｒ７活性化物質による膀胱の疾患の治療 |
| CN103497192B (zh) | 2008-12-09 | 2015-09-23 | 吉里德科学公司 | Toll样受体调节剂 |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| EP2396328A2 (en) | 2009-02-11 | 2011-12-21 | The Regents of The University of California | Toll-like receptor modulators and treatment of diseases |
| WO2010115229A1 (en) | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| SI2491035T1 (sl) | 2009-10-22 | 2017-10-30 | Gilead Sciences, Inc. | Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb |
| KR20130056249A (ko) | 2010-04-30 | 2013-05-29 | 텔로메딕스 에스에이 | 인지질 약물 유사체 |
| JP2013525431A (ja) * | 2010-04-30 | 2013-06-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 合成ｔｌｒ７アゴニストのリン脂質結合体の使用 |
| US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
| WO2012038058A1 (en) * | 2010-09-21 | 2012-03-29 | Telormedix Sa | Treatment of conditions by toll-like receptor modulators |
| PL3669892T3 (pl) * | 2010-09-22 | 2024-10-07 | Ena Respiratory Pty Ltd | Kompozycja do zastosowania w metodzie immunostymulacyjnej |
| GB201022049D0 (en) * | 2010-12-29 | 2011-02-02 | Imp Innovations Ltd | Methods |
| EP3208263A1 (en) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| ES2583877T3 (es) | 2011-06-01 | 2016-09-22 | Janus Biotherapeutics, Inc. | Moduladores novedosos del sistema inmunitario |
| GB201205360D0 (en) * | 2012-03-27 | 2012-05-09 | Univ Edinburgh | Biotinidase resistant biotinyl compounds |
| CN103254304A (zh) * | 2012-05-30 | 2013-08-21 | 深圳大学 | 免疫激动剂偶联体、其制备方法及免疫激动剂偶联体在抗肿瘤中的应用 |
| EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| WO2014052828A1 (en) | 2012-09-27 | 2014-04-03 | The Regents Of The University Of California | Compositions and methods for modulating tlr4 |
| CN105061567B (zh) * | 2012-10-10 | 2021-07-20 | 深圳大学 | 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物 |
| EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
| US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| EP2769738B1 (en) | 2013-02-22 | 2016-07-20 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| CN103467590B (zh) * | 2013-09-02 | 2016-04-13 | 深圳大学 | 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用 |
| CA2938280C (en) | 2014-04-22 | 2022-07-12 | F. Hoffmann-La Roche Ag | 4-amino-imidazoquinoline compounds |
| ES2908150T3 (es) * | 2014-05-01 | 2022-04-27 | Novartis Ag | Compuestos y composiciones como agonistas del receptor de tipo Toll 7 |
| JP6522732B2 (ja) | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| KR20190125537A (ko) | 2014-09-16 | 2019-11-06 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체 조정제의 고체 형태 |
| RU2712248C2 (ru) | 2015-03-06 | 2020-01-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензазепина дикарбоксамида |
| JP6893501B2 (ja) | 2015-09-17 | 2021-06-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン |
| DK3355933T3 (da) | 2015-09-29 | 2020-07-20 | Sumitomo Dainippon Pharma Co Ltd | Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser |
| CA3001283C (en) | 2015-10-07 | 2023-10-10 | Sumitomo Dainippon Pharma Co., Ltd. | Pyrimidine compound |
| RS65319B1 (sr) | 2015-12-17 | 2024-04-30 | Merck Patent Gmbh | 8-cijano-5-piperidino-hinolini kao tlr7/8 antagonisti i njihova upotreba u lečenju imunoloških poremećaja |
| CN109153648B (zh) | 2016-05-23 | 2022-07-22 | 豪夫迈·罗氏有限公司 | 具有叔酰胺官能团的苯并氮杂卓二甲酰胺化合物 |
| JP7022702B2 (ja) | 2016-05-23 | 2022-02-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
| EP3468963B1 (en) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
| MX390698B (es) | 2016-08-08 | 2025-03-11 | Merck Patent Gmbh | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. |
| CN106267188B (zh) * | 2016-08-15 | 2025-06-17 | 深圳大学 | 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用 |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) * | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| TW201915000A (zh) * | 2017-09-22 | 2019-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基衍生物、其製備方法及其在醫藥上的應用 |
| US11180510B2 (en) * | 2017-11-06 | 2021-11-23 | Centre National De La Recherche Scientifique | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins |
| FI3728289T3 (fi) | 2017-12-21 | 2025-11-11 | Axelia Oncology Pty Ltd | Optimoidut yhdisteet |
| CN108379591B (zh) | 2018-04-03 | 2022-03-29 | 深圳大学 | 免疫激动剂靶向化合物的合成及其应用 |
| US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
| TW202011986A (zh) | 2018-07-23 | 2020-04-01 | 公益財團法人日本健康科學振興財團 | 包含流感疫苗之組合物 |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| WO2020097398A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| JP7637328B2 (ja) * | 2019-02-07 | 2025-02-28 | ベイジーン リミテッド | Ｔｌｒ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体 |
| AU2020251582A1 (en) * | 2019-04-05 | 2021-12-02 | Sumitomo Pharma Co., Ltd. | Water soluble adjuvant |
| CA3136066A1 (en) | 2019-04-05 | 2020-10-08 | Sumitomo Dainippon Pharma Co., Ltd. | Water soluble adjuvant and composition containing same |
| CN114206378B (zh) | 2019-05-23 | 2024-10-25 | 蒙大拿大学 | 基于tlr受体配体的疫苗佐剂 |
| US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| KR20220050873A (ko) | 2019-06-26 | 2022-04-25 | 악셀리아 온콜로지 피티와이 리미티드 | 신규한 분자 |
| JP7595643B2 (ja) * | 2019-08-02 | 2024-12-06 | ベイジーン リミテッド | Ｔｌｒ８アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体 |
| CA3144902A1 (en) | 2019-08-14 | 2022-01-19 | Andreas Thess | Rna combinations and compositions with decreased immunostimulatory properties |
| WO2021084022A1 (en) * | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| EP4061816A1 (en) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| CN115135655B (zh) | 2020-01-27 | 2024-07-02 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| CN115151546A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物 |
| WO2021154664A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097102A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| WO2021154663A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| WO2021154666A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132602A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| WO2021154668A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097103A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| CN111704614B (zh) * | 2020-04-15 | 2021-10-22 | 深圳大学 | 一种系列免疫激动剂 |
| WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
| CN114315861A (zh) * | 2020-09-27 | 2022-04-12 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
| CA3196221A1 (en) | 2020-10-21 | 2022-04-28 | Univerza V Ljubljani | Conjugated tlr7 and nod2 agonists |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| PE20240587A1 (es) | 2021-05-26 | 2024-03-21 | Novartis Ag | Analogos de triazolo-pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn) |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| JP2025540756A (ja) * | 2022-12-05 | 2025-12-16 | 江蘇恒瑞医薬股▲ふん▼有限公司 | トリアゾール化合物、その製造方法と医薬的用途 |
| WO2024255765A1 (en) * | 2023-06-12 | 2024-12-19 | Nuphase Therapeutics (Hangzhou) Limited., Co. | Novel compounds, compositions comprising the same and uses thereof |
| WO2025040743A1 (en) | 2023-08-22 | 2025-02-27 | Univerza V Ljubljani | Conjugated tlr7 and rig-i agonists |
| WO2025093657A1 (en) | 2023-10-31 | 2025-05-08 | Univerza V Ljubljani | Conjugated tlr7 and tlr4 agonists |
| CN120424093A (zh) * | 2024-02-02 | 2025-08-05 | 中国科学院上海药物研究所 | 螺环类化合物、包含其的药物组合物及其用途 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699908A (en) | 1955-01-18 | fletcher | ||
| CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5736553A (en) * | 1988-12-15 | 1998-04-07 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine |
| US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US5037986A (en) * | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
| US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| NZ232740A (en) | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| ES2071340T3 (es) | 1990-10-05 | 1995-06-16 | Minnesota Mining & Mfg | Procedimiento para la preparacion de imidazo(4,5-c)quinolin-4-aminas. |
| US5175296A (en) | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5648516A (en) * | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5525606A (en) * | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
| DE19505168A1 (de) * | 1995-02-16 | 1996-08-22 | Boehringer Mannheim Gmbh | Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel |
| US5624677A (en) * | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5693811A (en) | 1996-06-21 | 1997-12-02 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahdroimidazoquinolinamines |
| US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
| DE19637209B4 (de) * | 1996-09-12 | 2006-12-14 | Siemens Ag | Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung |
| WO1998017279A1 (en) | 1996-10-25 | 1998-04-30 | Minnesota Mining And Manufacturing Company | Immune response modifier compounds for treatment of th2 mediated and related diseases |
| CA2309350C (en) * | 1997-11-12 | 2007-04-03 | Mitsubishi Chemical Corporation | Purine derivatives and medicaments comprising the same as active ingredient |
| AU732361B2 (en) | 1997-11-28 | 2001-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compounds |
| US7001609B1 (en) * | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
| CA2361936C (en) * | 1999-01-08 | 2009-06-16 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| US20020058674A1 (en) * | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
| US6486168B1 (en) * | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| ATE322494T1 (de) * | 2000-01-07 | 2006-04-15 | Universitaire Instelling Antwe | Purin derivate, ihre herstellung und verwendung |
| US6733764B2 (en) * | 2000-06-14 | 2004-05-11 | Alain Martin | Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer |
| WO2002023186A2 (en) * | 2000-09-15 | 2002-03-21 | Virco Bvba | System and method for optimizing drug therapy for the treatment of diseases |
| US20020127224A1 (en) * | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
| DK1385823T3 (da) * | 2001-04-09 | 2007-03-26 | Novartis Vaccines & Diagnostic | Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister |
| US7157465B2 (en) * | 2001-04-17 | 2007-01-02 | Dainippon Simitomo Pharma Co., Ltd. | Adenine derivatives |
| EP1401837B1 (en) * | 2001-06-29 | 2005-10-19 | Cv Therapeutics, Inc. | Purine derivatives as a2b adenosine receptor antagonists |
| AU2002343604C1 (en) * | 2001-10-30 | 2009-09-17 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| AU2003271064B2 (en) * | 2002-09-27 | 2010-06-17 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound and use thereof |
| CN100387710C (zh) * | 2003-01-28 | 2008-05-14 | 上海三维生物技术有限公司 | 原发性癌和转移性癌相关的核酸 |
| US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| US20050004144A1 (en) * | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
| US20050059613A1 (en) * | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| WO2005020892A2 (en) * | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| OA13310A (en) | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
| JP2005089334A (ja) | 2003-09-12 | 2005-04-07 | Sumitomo Pharmaceut Co Ltd | ８−ヒドロキシアデニン化合物 |
| BRPI0414533A (pt) * | 2003-09-18 | 2006-11-07 | Conforma Therapeutics Corp | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 |
| FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
| JP2007526322A (ja) * | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| MXPA06011080A (es) * | 2004-03-26 | 2007-04-16 | Astrazeneca Ab | Compuesto de 8-oxoadenina 9-sustituido. |
| CA2587676A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| BRPI0609399A2 (pt) | 2005-03-21 | 2010-03-30 | Ferrer Int | método para produzir compostos da 1h-imidazo[4,5-c]quinolin-4-amina 1-substituìda e intermediários dos mesmos |
| US20070292418A1 (en) * | 2005-04-26 | 2007-12-20 | Eisai Co., Ltd. | Compositions and methods for immunotherapy |
| CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| US20090118263A1 (en) * | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
| JPWO2007034917A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
| EA200800943A1 (ru) | 2005-09-27 | 2008-12-30 | Коли Фармасьютикал Гмбх | Модуляция tlr-опосредуемых иммунных ответов с использованием олигонуклеотидов-адаптеров |
| US20070100146A1 (en) * | 2005-11-03 | 2007-05-03 | Trevor Dzwiniel | Process for the preparation of imidazo[4,5-c]-quinolin-4-amines |
| CA2653941C (en) | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Substituted amino purine derivatives and uses thereof |
| US8338593B2 (en) * | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| WO2008043031A1 (en) * | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| EA019151B1 (ru) * | 2007-02-07 | 2014-01-30 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Конъюгаты синтетических агонистов tlr и их применение |
| JP5395068B2 (ja) * | 2007-06-29 | 2014-01-22 | ギリアード サイエンシーズ， インコーポレイテッド | トール様受容体７の調節物質としてのプリン誘導体およびその使用 |
| EP2200615A1 (en) * | 2007-10-16 | 2010-06-30 | Gilead Palo Alto, Inc. | A3 adenosine receptor antagonists |
| JP2011511073A (ja) | 2008-02-07 | 2011-04-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｌｒ７活性化物質による膀胱の疾患の治療 |
| WO2010088924A1 (en) * | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| EP2396328A2 (en) | 2009-02-11 | 2011-12-21 | The Regents of The University of California | Toll-like receptor modulators and treatment of diseases |
| SI2491035T1 (sl) * | 2009-10-22 | 2017-10-30 | Gilead Sciences, Inc. | Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb |
| KR20130056249A (ko) * | 2010-04-30 | 2013-05-29 | 텔로메딕스 에스에이 | 인지질 약물 유사체 |
| JP2013525431A (ja) * | 2010-04-30 | 2013-06-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 合成ｔｌｒ７アゴニストのリン脂質結合体の使用 |
| AU2011247359A1 (en) * | 2010-04-30 | 2012-11-15 | Telormedix Sa | Methods for inducing an immune response |
| BR112013005134A2 (pt) * | 2010-09-01 | 2018-04-24 | Novartis Ag | adsorção de imunopotenciadores em sais metálicos insolúveis |
| WO2012038058A1 (en) * | 2010-09-21 | 2012-03-29 | Telormedix Sa | Treatment of conditions by toll-like receptor modulators |
-
2010
- 2010-02-11 EP EP10706399A patent/EP2396328A2/en not_active Withdrawn
- 2010-02-11 CN CN201080016320.6A patent/CN102439011B/zh not_active Expired - Fee Related
- 2010-02-11 WO PCT/US2010/000369 patent/WO2010093436A2/en not_active Ceased
- 2010-02-11 MX MX2011008500A patent/MX2011008500A/es active IP Right Grant
- 2010-02-11 CA CA2752074A patent/CA2752074A1/en not_active Abandoned
- 2010-02-11 US US12/704,343 patent/US8729088B2/en active Active
- 2010-02-11 JP JP2011549168A patent/JP2012517428A/ja active Pending
- 2010-02-11 SG SG2011057429A patent/SG173617A1/en unknown
- 2010-02-11 KR KR1020117021190A patent/KR20110117705A/ko not_active Ceased
- 2010-02-11 AU AU2010214112A patent/AU2010214112B2/en not_active Ceased
- 2010-02-11 EP EP13001458.2A patent/EP2607365A1/en not_active Withdrawn
- 2010-02-11 BR BRPI1008383A patent/BRPI1008383A2/pt not_active IP Right Cessation
- 2010-02-11 EA EA201101165A patent/EA019768B1/ru not_active IP Right Cessation
-
2011
- 2011-08-09 IL IL214572A patent/IL214572A/en not_active IP Right Cessation
- 2011-08-25 ZA ZA2011/06268A patent/ZA201106268B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517428A5 (cg-RX-API-DMAC7.html) | ||
| CA2754808C (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
| ES2243441T3 (es) | Derivados de imidazolio fundidos. | |
| EP2131840B1 (en) | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent | |
| AR067599A1 (es) | Derivados de indazol sustituido activos como inhibidores de quinasa | |
| ES2576497T3 (es) | Compuesto de piperidina novedoso o sal del mismo | |
| EP3678668A1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| CN101370497A (zh) | 利用parp抑制剂的联合疗法 | |
| AU2015317566A1 (en) | Benzo-heterocyclic compounds and their applications | |
| JP2008535902A5 (cg-RX-API-DMAC7.html) | ||
| JP2008517984A5 (cg-RX-API-DMAC7.html) | ||
| JP2009541223A5 (cg-RX-API-DMAC7.html) | ||
| JP2011132222A5 (cg-RX-API-DMAC7.html) | ||
| CA3138197A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| JP2013540114A5 (cg-RX-API-DMAC7.html) | ||
| JP2016522202A (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| WO2009002553A1 (en) | Methods of treating multiple myeloma and resistant cancers | |
| JP2007500734A5 (cg-RX-API-DMAC7.html) | ||
| JP2018529648A5 (cg-RX-API-DMAC7.html) | ||
| JP2005526794A5 (ja) | ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用 | |
| JPWO2008001502A1 (ja) | 放射線治療増強剤 | |
| JP2014526526A5 (cg-RX-API-DMAC7.html) | ||
| JP2017137323A (ja) | 新規抗がん剤 | |
| WO2011073092A1 (en) | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | |
| JP2013525290A5 (cg-RX-API-DMAC7.html) |